Abstract
Soluble tumor necrosis factor receptors (TNFRs) are important modulators of TNF bioactivity. Proteolytic cleavage of the 28-kDa ectodomain of TNFR1 has been recognized as the mechanism by which soluble TNFR is shed. We now describe the release of exosome-like vesicles as a mechanism for the generation of soluble, full-length 55-kDa TNFR1. We found unexpectedly that the predominant form of soluble TNFR1 in human serum and lung epithelial lining fluid is a full-length 55-kDa protein. Furthermore, supernatants from human vascular endothelial cells contain only full-length 55-kDa TNFR1 that can be sedimented by high-speed centrifugation, floated on sucrose gradients at a density of 1.1 g/ml, and associated with vesicles that range in diameter from 20 nm to 50 nm. We conclude that the release of TNFR1 exosome-like vesicles represents a previously unrecognized mechanism by which constitutive production of soluble cytokine receptors may be regulated, independent of ectodomain cleavage by receptor sheddases.
MeSH Terms
Antigens, CD/analysis,blood,metabolism
Catalysis
Endothelial Cells/chemistry
Epithelium/chemistry
Humans
Lung/chemistry
Membrane Microdomains/chemistry
Metalloproteases/physiology
Receptors, Tumor Necrosis Factor/analysis,blood,metabolism
Receptors, Tumor Necrosis Factor, Type I
Tumor Necrosis Factor-alpha/metabolism
Chemicals
Antigens, CD
Receptors, Tumor Necrosis Factor
Receptors, Tumor Necrosis Factor, Type I
Tumor Necrosis Factor-alpha
Metalloproteases
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Hawari Feras I
Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Rouhani Farshid N
Cui Xinle
Yu Zu-Xi
Buckley Caitriona
Kaler Maryann
Levine Stewart J
References (26)
26 references, click to expand
-
Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules.
Blood. 1999 Dec 1;94(11):3791-9
PMID: 10572093
-
In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.
J Clin Invest. 1999 Jul;104(1):93-102
PMID: 10393703
-
Exosome: from internal vesicle of the multivesicular body to intercellular signaling device.
J Cell Sci. 2000 Oct;113 Pt 19:3365-74
PMID: 10984428
-
Rapid secretion of interleukin-1beta by microvesicle shedding.
Immunity. 2001 Nov;15(5):825-35
PMID: 11728343
-
TNF-R1 signaling: a beautiful pathway.
Science. 2002 May 31;296(5573):1634-5
PMID: 12040173
-
Exosomes: composition, biogenesis and function.
Nat Rev Immunol. 2002 Aug;2(8):569-79
PMID: 12154376
-
Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding.
J Clin Invest. 2002 Aug;110(4):515-26
PMID: 12189246
-
Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation.
Immunity. 2003 May;18(5):655-64
PMID: 12753742
-
Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool.
J Biol Chem. 2003 Jun 13;278(24):21751-60
PMID: 12646554
-
Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes.
Cell. 2003 Jul 25;114(2):181-90
PMID: 12887920
-
Isolation and characterization of a tumor necrosis factor binding protein from urine.
Eur J Haematol. 1989 Mar;42(3):270-5
PMID: 2924890
-
Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor.
J Biol Chem. 1989 Jul 15;264(20):11966-73
PMID: 2545692
-
A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.
J Biol Chem. 1989 Jul 15;264(20):11974-80
PMID: 2545693
-
Molecular cloning and expression of a receptor for human tumor necrosis factor.
Cell. 1990 Apr 20;61(2):361-70
PMID: 2158863
-
Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor.
EMBO J. 1990 Oct;9(10):3269-78
PMID: 1698610
-
Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity.
J Biol Chem. 1991 Sep 25;266(27):18324-9
PMID: 1655744
-
Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.
J Exp Med. 1992 Feb 1;175(2):323-9
PMID: 1310100
-
Structural requirements for inducible shedding of the p55 tumor necrosis factor receptor.
J Biol Chem. 1994 Dec 23;269(51):32488-96
PMID: 7798250
-
Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells.
Am J Pathol. 1995 Jan;146(1):27-32
PMID: 7856733
-
A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor.
J Immunol. 1995 Dec 1;155(11):5198-205
PMID: 7594530
-
B lymphocytes secrete antigen-presenting vesicles.
J Exp Med. 1996 Mar 1;183(3):1161-72
PMID: 8642258
-
The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection.
J Clin Invest. 1997 Apr 1;99(7):1546-54
PMID: 9119998
-
Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes.
J Biol Chem. 1998 Aug 7;273(32):20121-7
PMID: 9685355
-
TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1.
J Immunol. 1999 Jan 15;162(2):1042-8
PMID: 9916731
-
Prevention of constitutive TNF receptor 1 signaling by silencer of death domains.
Science. 1999 Jan 22;283(5401):543-6
PMID: 9915703
-
Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme.
J Biol Chem. 2000 May 12;275(19):14608-14
PMID: 10799547